This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Update on perioperative systemic therapy for urothelial carcinoma
Clin Adv Hematol Oncol. 2019 Mar;17(3) :176-183
PMID: 30969956 URL: https://www.ncbi.nlm.nih.gov/pubmed/30969956
AbstractLevel 1 evidence supports cisplatin-based neoadjuvant chemotherapy (NAC) in muscle-invasive urothelial bladder cancer (MIUBC). Recent data from small prospective trials with neoadjuvant immune checkpoint inhibitors are encouraging, but long-term follow-up is required. Randomized trials have failed to accrue a sufficient number of patients and have not demonstrated a survival benefit with adjuvant chemotherapy in MIUBC, but for those with high-risk features at surgery, adjuvant cisplatin-based therapy is appropriate. In upper tract urothelial carcinoma, several retrospective trials and one recent phase 2 prospective trial support the use of NAC, and a randomized trial with adjuvant chemotherapy demonstrated improved disease- and metastasis-free survival and a trend toward improved overall survival.
NotesRouvinov, Keren Plimack, Elizabeth R Zibelman, Matthew Ghatalia, Pooja Geynisman, Daniel M Journal Article Review United States Clin Adv Hematol Oncol. 2019 Mar;17(3):176-183.